CCG-14223 was an inhibitor for Rho/SRF pathway and displayed activity in several in vitro cancer cell functional assays. In PC-3 prostate cancer cells, CCG-1423(< 1 μmol/L) potently inhibited lysophosphatidic acid-induced DNA synthesis. CCG-1423 inhibited the growth of RhoC-overexpressing melanoma lines at nanomolar concentrations. CCG-1423 selectively stimulated apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell line when compared with the parental cell line. CCG-1423 inhibited Rho-dependent invasion by PC-3 prostate cancer cells. The S-isomer of CCG-1423 inhibited MRTF-A-dependent cellular events, including SRF-mediated gene expression and cell migration. The efficacy of (S)-CCG-1423 was more potent than the R-isomer [1][2].